Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Adenylate-Uridylate-rich element-containing messenger RNAs (ARE-mRNAs) are a class of transcripts characterized by specific AU-rich motifs, most commonly the AUUUA pentamer, located within their 3' untranslated regions (3'UTRs) (Khabar, 2017). These elements serve as critical post-transcriptional regulatory signals that dictate the stability and translational efficiency of the mRNA by recruiting various AU-rich element-binding proteins (ARE-BPs) (Garcia-Maurino et al., 2017). In healthy cells, AREs ensure the rapid turnover of potent signaling molecules such as cytokines (e.g., TNF-alpha, IL-6) and proto-oncogenes (e.g., MYC, FOS), allowing for transient and tightly controlled gene expression (Bakheet et al., 2018). Dysregulation of the ARE-mediated pathway, often through the overexpression of stabilizing proteins like HuR (ELAVL1) or the loss of destabilizing proteins like Tristetraprolin (TTP/ZFP36), leads to the pathological stabilization of these mRNAs, contributing to chronic inflammation and oncogenesis (Wu et al., 2019). Therapeutic strategies targeting ARE-mRNAs primarily focus on small molecules that disrupt the interaction between AREs and stabilizing RBPs or antisense oligonucleotides designed to modulate the decay of specific ARE-containing transcripts (Muralidharan et al., 2017). Because AREs are present in approximately 5-10% of all human genes, targeting this pathway offers a broad therapeutic window for treating diverse pathologies but also presents significant challenges regarding specificity and potential off-target effects (Khabar, 2017). Small molecule inhibitors like MS-444 and CMLD-2 have demonstrated efficacy in preclinical models by preventing the stabilization of oncogenic ARE-mRNAs by HuR (Meisner et al., 2007). Overall, ARE-mRNAs represent a pivotal node in gene regulation that is increasingly being explored for its potential in precision medicine and RNA-targeted drug discovery.
Inhibition of RNA-binding protein (RBP) recruitment to AU-rich elements, leading to increased mRNA decay or decreased translation.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Adenylate-Uridylate-rich element-containing messenger RNA (ARE-mRNA) (ARE-mRNA).